Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jazz Pharmaceuticals Q3 Adj. EPS $8.13 Beats $5.92 Estimate, Sales $1.126B Beat $1.109B Estimate

Author: Benzinga Newsdesk | November 05, 2025 04:15pm
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $8.13 per share which beat the analyst consensus estimate of $5.92 by 37.35 percent. This is a 24.31 percent increase over earnings of $6.54 per share from the same period last year. The company reported quarterly sales of $1.126 billion which beat the analyst consensus estimate of $1.109 billion by 1.58 percent. This is a 6.73 percent increase over sales of $1.055 billion the same period last year.

Posted In: JAZZ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist